{
    "nct_id": "NCT06392789",
    "official_title": "A Crossover Randomized Controlled Trial to Investigate the Acceptability and Efficacy of Cecebot, a Conversational Agent for Insomnia After Breast Cancer",
    "inclusion_criteria": "* Age ≥ 18 years\n* Prior diagnosis of stage I-III invasive breast cancer\n* Female gender\n* Clinically significant insomnia symptoms, defined as a Patient Reported Outcomes Measurement Information System (PROMIS) Sleep Disturbance 8 T-score of 60 or greater\n* Insomnia complaints lasting ≥ 3 months\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0-2, indicating ability to perform activities of daily living\n* Own a smartphone with Internet connectivity\n* Willing and able to complete the intervention with personal smartphone\n* Proficient in speaking and reading English\nHealthy volunteers allowed\nMust be FEMALE\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Prior diagnosis of restless leg syndrome, periodic leg movement disorder, narcolepsy, or rapid eye movement (REM) behavior disorder\n* Current sleep apnea (treated or untreated)\n* Current shiftwork\n* Actively receiving chemotherapy or radiation (endocrine therapy permitted)\n* Previously received CBTi therapy with a professional therapist\n* Contraindications to CBTi including:\n\n  * Active psychosis\n  * Uncontrolled bipolar disorder\n  * Severe depression\n  * Active substance use disorder (moderate or greater severity)\n* Use of prescribed sleep medication > 3 times per week\n* Previously participated in user testing of the study intervention (Cecebot)\n* Unwilling or unable to complete study procedures",
    "miscellaneous_criteria": ""
}